In biochemistry and medicine, glycoprotein IIb/IIIa (GPIIb/IIIa, also known as integrin αIIbβ3) is an integrin complex found on platelets. It is a transmembrane receptor for fibrinogen [1] and von Willebrand factor, and aids platelet activation.

In medicine, glycoprotein IIb/IIIa inhibitors, also GpIIb/IIIa inhibitors, is a class of antiplatelet agents. Several GpIIb/IIIa inhibitors exist: Glycoprotein IIb/IIIa inhibitors are frequently used during percutaneous coronary intervention (angioplasty with or without intracoronary stent placement).

2023年7月25日 · Glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitors prevent platelet aggregation by blocking glycoprotein IIb/IIIa receptors; thus, they found application in the management of coronary artery disease (CAD). The available GP IIb/IIIa …

Glycoprotein platelet inhibitors prevent platelet adhesion by binding to the glycoprotein IIb/IIIa receptors on the plasma membrane of platelets.

2022年11月17日 · Glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitors block subunits α and β on glycoprotein receptors of the platelet’s membrane. The GPIIb/IIIa receptor is the primary platelet receptor in platelet aggregation. This inhibition interferes with …

2005年3月22日 · IIb/IIIa inhibitors, especially abciximab, may become a standard in angioplasty for STEMI if the ongoing randomised trials confirm the efficacy and safety of its early use. New evidence is modifying the role of Glycoprotein IIb/IIIa inhibitors during PCI as defined by the current guidelines.

Endovascular treatment has become a mainstay of treatment for patients with peripheral arterial disease (PAD) and symptomatic limb ischemia. Available treatment options are diverse and include percutaneous transluminal angioplasty, stent placement, atherectomy, thrombolysis, and …

Glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitors are a class of drugs that work by preventing the formation of blood clots by inhibiting the action of platelets. Because of their actions on the platelets, GP IIb/IIIa inhibitors are also called antiplatelet therapies and are prescribed in cases of serious heart conditions.

Platelet membrane glycoproteins are involved in platelet adhesion and aggregation. Glycoproteins IIb and IIIa (GPIIb and GPIIIa) constitute the fibrinogen receptor and are required for platelet aggregation. ERL offers GPIIbIIIa purified from human platelets.

Glycoprotein IIb-IIIa inhibitors (GPI) remain the most powerful antiplatelet agents by inhibiting this final common pathway of platelet activation. The role of GPI in the treatment of coronary ischemic events has evolved through the past 20 years.

In this review, we aimed to assess the safety and efficacy of prophylactic GP2B3A inhibitor use and to compare the performance of GP2B3A inhibitors with oral dual antiplatelet (DAP) treatment in intracranial aneurysm patients treated with stent-assisted coil embolization or flow diversion.

The human glycoprotein (GP)IIb/IIIa belongs to a large family of cation-dependent adhesion molecules known as integrins, which share a common heterodimeric structure. The primary function of GPIIb/IIIa is to aid platelet aggregation by transmitting bidirectional signals across the plasma membrane.

1999年7月27日 · Glycoprotein (GP) IIb/IIIa (α IIb β 3) serves as the receptor on platelets that binds plasma-borne adhesive proteins, such as fibrinogen and von Willebrand factor (vWF), to permit platelet aggregation. 2 Aggregation is mediated by this pathway, irrespective of the agonist that stimulates platelets and irrespective of the stimulus-response–coupli...

Glycoprotein 2b3a inhibitors represent a promising class of antiplatelet medications. Their use in acute coronary syndromes and in patients undergoing percutaneous coronary intervention has been the subject of a number of large controlled trials, including tens of thousands of patients.

Glycoprotein (GP) IIb-IIIa antagonists inhibit the aggregation of activated platelets. Three agents are approved for clinical use. In this review, the characteristics of each agent, their pharmacodynamic profile, results in pivotal clinical trials and …

2007年2月1日 · Glycoprotein (GP) IIb-IIIa inhibitors block the final common pathway to platelet aggregation antagonizing with receptors that bind fibrinogen molecules forming bridges between adjacent platelets.

Derived from the NIH UMLS (Unified Medical Language System) A class of agents that act by selectively inhibiting glycoprotein IIb/IIIa with anticoagulant activity.

GP IIb/IIIa antagonists have their mechanism of action in platelet aggregation prevention, distal thromboembolism, and thrombus formation, whereas the initial platelet binding to damage vascular areas is preserved. This work is aimed to provide a comprehensive review of the significance of GP IIb/IIIa inhibitors as a sort of antiplatelet agent.

2022年12月1日 · In this review, we aimed to assess the safety and efficacy of prophylactic GP2B3A inhibitor use and to compare the performance of GP2B3A inhibitors with oral dual antiplatelet (DAP) treatment in intracranial aneurysm patients treated with stent-assisted coil embolization or flow diversion.

2002年7月16日 · Glycoprotein (GP) IIb/IIIa antagonists are potent inhibitors of platelet aggregation that provide marked protection from ischemic events in patients undergoing percutaneous coronary intervention (PCI). 1,2 Abciximab, the prototypic GP IIb/IIIa inhibitor, has been studied in >8000 patients undergoing elective or high-risk PCI. 2,3,4 In these pati...